Skip to main content
34°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about Eisai Co Ltd
Recent news which mentions Eisai Co Ltd
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
April 24, 2024
Tags
Companies
Breaking news
Health & Science
From
CNBC.com News
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
March 08, 2024
Tags
Biotechnology
US: News
Business News
From
CNBC.com News
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
February 20, 2024
Tags
Healthy Returns
Health & Science
Biotech and Pharmaceuticals
From
CNBC.com News
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
February 13, 2024
Tags
Companies
Breaking news
Biogen Inc
From
CNBC.com News
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
January 31, 2024
Tags
Business News
Social issues
US: News
From
CNBC.com News
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
December 20, 2023
Tags
Amgen Inc
Eli Lilly and Co
Eisai Co Ltd
From
CNBC.com News
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
December 02, 2023
Tags
Pfizer Inc
Sanofi SA
Health & Science
From
CNBC.com News
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
October 25, 2023
Tags
Business
Biotech and Pharmaceuticals
Eisai Co Ltd
From
CNBC.com News
5 things to know before the stock market opens Tuesday
July 18, 2023
Tags
Biogen Inc
Bank of America Corp
Technology
From
CNBC.com News
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
July 17, 2023
Tags
Eli Lilly and Co
Eisai Co Ltd
Business
From
CNBC.com News
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
July 08, 2023
Tags
Science
Breaking News: Business
Alzheimer's disease
From
CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
July 07, 2023
Tags
Law and Regulation
Social issues
US: News
From
CNBC.com News
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
July 07, 2023
Tags
Economy
DraftKings Inc
First Solar Inc
From
CNBC.com News
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
July 07, 2023
Tags
Asia Markets
Science
Biotech and Pharmaceuticals
From
CNBC.com News
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
July 06, 2023
Tags
Social issues
World News
US: News
From
CNBC.com News
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval
June 09, 2023
Tags
Pandemics
Biotech and Pharmaceuticals
Business
From
CNBC.com News
Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action
June 07, 2023
Tags
Alzheimer's disease
Policy
Politics
From
CNBC.com News
Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
May 12, 2023
Tags
Biotech and Pharmaceuticals
Business
Eli Lilly and Co
From
CNBC.com News
Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments
May 01, 2023
Tags
Breaking News: Business
Policy
Epidemics
From
CNBC.com News
Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
April 30, 2023
Tags
U/S/ Economy
Business News
Disease outbreaks
From
CNBC.com News
Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says
April 26, 2023
Tags
Biogen Inc
Health care industry
Health & Science
From
CNBC.com News
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
April 25, 2023
Tags
US: News
Biotechnology
Business News
From
CNBC.com News
Alzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai says
April 06, 2023
Tags
Biotechnology
US: News
Biotech and Pharmaceuticals
From
CNBC.com News
Eli Lilly says experimental Alzheimer's drug reduces brain plaque in early study
April 05, 2023
Tags
Companies
Breaking news
Breaking News: Business
From
CNBC.com News
Veterans' Health will cover Alzheimer's treatment Leqembi for some patients
March 13, 2023
Tags
Business News
World News
US: News
From
CNBC.com News
FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July
March 06, 2023
Tags
Business News
World News
US: News
From
CNBC.com News
Medicare rejects Alzheimer's Association request for unrestricted coverage of treatments like Leqembi
February 23, 2023
Tags
Health care industry
Biogen Inc
US Top News and Analysis
From
CNBC.com News
Senators call on Medicare to offer broad coverage of Alzheimer's treatments as public pressure grows
February 17, 2023
Tags
Breaking News: Business
Epidemics
Policy
From
CNBC.com News
Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage
February 17, 2023
Tags
Biotech and Pharmaceuticals
Business
US Economy
From
CNBC.com News
FDA approves Alzheimer's drug that slowed cognitive decline in clinical trial
January 06, 2023
Tags
U/S/ Economy
Business News
Disease outbreaks
From
CNBC.com News
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.